Through the first half of the 2021 financial year, the Company undertook a strategic capital raise to support the ongoing scientific research and prepare the Company for a planned IPO in the coming 12 – 24 months.

The relevant resolutions were passed by shareholders at the General Meeting held in December 2020, and the strategic capital raise was completed in March 2021.  The efforts of the Board, together with Lodge Partners, has resulted in the placement of 82,191,781 ordinary shares at a share price of $0.0146 and $2,750,000 of capital via convertible notes (converting at a share price of $0.0146).

The Board acknowledges and thanks Lodge Partners for their dedication to this project and the successful outcome achieved and welcomes new investors to Imunexus Therapeutics.